ICE方案联合利妥昔单抗对难治性弥漫大B细胞淋巴瘤FOXP1与Livin表达影响研究

摘要

Objective:To investigate the effect of CHOP combined with rituximab on the expression of FOXP 1 and Livin in refractory diffuse large B-cell lymphoma .Methods:78 patients with refractory diffuse large B cell lym-phoma form our department were selected and divided into 2 groups ,control group (n=39) and study group (n=39) .The control group was treated with CHOP regimen .The study group were treated CHOP combined with ritux-imab treatment ,every 21 days for a cycle ,the two groups were treated for 4 courses ,the expressions of FOXP1 and Livin were detected by immunohistochemistry Envision method .The clinical efficacy of the two groups was com-pared with that of the two groups .The survival status and the toxicity status were observed and recorded .Results :The effective rate of the control group 71 .80% was lower than the study group (89 .74% )(P<0 .05) .Compared with before treatment ,the positive rate of FOXP1 expression decreased in 2 groups (P<0 .05) ,compared with the control group ,the positive rate of FOXP1 expression was lower in the study group (P<0 .05) .Compared with be-fore treatment ,the positive rate of Livin expression decreased in the study group (P<0 .05) ,compared with the con-trol group ,the positive rate of Livin expression was lower in the study group (P<0 .05) .The 3-year survival rate (74 .36% ,66 .67% ) in the study group was higher than that the control group (61 .54% ,48 .72% )(P< 0 .05) . There was no significant difference in the incidence of adverse reactions between the two groups (P> 0 .05) .Con-clusion:CHOP combined with rituximab has a good effect on refractory diffuse large B cell lymphoma ,reducing the expression of FOXP1 and Livin ,improving the survival rate and high safety .%目的:探讨ICE方案联合利妥昔单抗对难治性弥漫大B细胞淋巴瘤FOXP1与Livin表达的影响.方法:选取难治性弥漫大B细胞淋巴瘤患者78例,按照治疗方案不同分为对照组和研究组,各39例.对照组采用IC E方案治疗,研究组采用IC E方案联合利妥昔单抗治疗,每21天为1个周期,两组共治疗4个疗程,治疗前后取肿瘤组织切片采用免疫组织化学Envision法检测FOXP1与Livin表达水平,对比两组间临床疗效,同时进行随访,观察和记录生存状况以及不良反应情况.结果对照组治疗有效率71.80%低于研究组89.74%(P<0.05);与治疗前比较,研究组治疗后FOXP1表达阳性率降低(P<0.05),与对照组比较,研究组治疗后FOXP1表达阳性率较低(P<0.05);与治疗前比较,研究组治疗后Livin表达阳性率降低(P<0.05),与对照组比较,研究组治疗后Livin表达阳性率较低(P<0.05);研究组随访第2年、3年生存率(74.36%、66.67%)高于对照组(61.54%、48.72%),有统计学差异(P<0.05);两组间不良反应发生率对比,统计学无差异(P>0.05).结论:ICE方案联合利妥昔单抗对难治性弥漫大B细胞淋巴瘤疗效确切,降低FOXP1与Livin表达,提高生存率,安全性高.